Sacituzumab tirumotecan

芦康沙妥珠单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameSacituzumab tirumotecan
Drug Alias Name佳泰莱SKB-264MK-2870SKB264sac-TMT
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > CL2A linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > KL610023 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Trop-2DNA topoisomerase I inhibitors
TargetsTumor-associated calcium signal transducer 2DNA topoisomerase I
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerGastroesophageal Junction Neoplasms +[32] 
Global Approved IndicationsTriple Negative Breast Neoplasms
Approved Indications in ChinaTriple Negative Breast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2024/11/22
Country/TerritoryCzechiaBelgiumBulgaria +[51] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFujian Cancer HospitalYale UniversityThe University Of Texas MD Anderson Cancer Center +[9] 
Inactive CompaniesShanghai Jiao Tong University School of Medicine
Active IndicationsBrain metastasesMetastatic breast cancerGastroesophageal Junction Neoplasms +[32] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A